Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL356238 | 0.79 | KMT2A (0.38) | KMT2AMEN1NPC1CYP1A2CYP2C19 | |
| SCHEMBL2016182 | 0.75 | KMT2A (0.36) | KMT2AMEN1NPC1CYP1A2CYP2C19 | |
| SCHEMBL6044102 | 0.74 | KMT2A (0.42) | KMT2AMEN1NPC1CYP1A2CYP2C19 | |
| SCHEMBL5564599 | 0.74 | HRH3 (0.36) | KMT2AMEN1NPC1CYP1A2CYP2C19 | |
| SCHEMBL178610 | 0.72 | KMT2A (0.45) | KMT2AMEN1NPC1CYP1A2CYP2C19 | |
| SCHEMBL6039419 | 0.72 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL19627823 | 0.72 | KMT2A (0.41) | KMT2AMEN1NPC1CYP1A2CYP2C19 | |
| SCHEMBL6044110 | 0.72 | KMT2A (0.41) | KMT2AMEN1NPC1CYP1A2CYP2C19 | |
| SCHEMBL18818612 | 0.72 | KMT2A (0.41) | KMT2AMEN1NPC1CYP1A2CYP2C19 | |
| SCHEMBL25697924 | 0.72 | KMT2A (0.41) | KMT2AMEN1NPC1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115611856-B | Piperidine derivative and pharmaceutical composition, preparation method and application thereof | 宜昌人福药业有限责任公司 | 2024-07-05 | — | — | CN | claimed |
| EP-3750894-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2024-04-03 | — | — | EP | claimed |
| EP-4345096-A1 | PIPERIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Yichang Humanwell Pharmaceutical Co., Ltd. (CN) | 2024-04-03 | — | — | EP | claimed |
| WO-2024052512-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-14 | — | — | WO | claimed |
| CN-117642389-A | Piperidine derivative and pharmaceutical composition, preparation method and application thereof | 宜昌人福药业有限责任公司 | 2024-03-01 | — | — | CN | claimed |
| EP-3590941-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | claimed |
| EP-3750893-B1 | DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-04-19 | — | — | EP | claimed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | claimed |
| CN-115611856-A | Piperidine derivative and pharmaceutical composition, preparation method and application thereof | 宜昌人福药业有限责任公司 | 2023-01-17 | — | — | CN | claimed |
| EP-3298011-B1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-11-17 | — | — | EP | claimed |
| EP-1226126-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-01-05 | — | — | EP | claimed |
| US-6809097-B1 | ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY | ZENECA LIMITED (GB) | 2004-10-26 | — | — | US | claimed |
| EP-1226126-A1 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2002-07-31 | — | — | EP | claimed |
| US-6294532-B1 | TREATMENT OF A NUMBER OF DISEASE STATES INCLUDING CANCER AND RHEUMATOID ARTHRITIS. | ZENECA LIMITED (GB) | 2001-09-25 | — | — | US | claimed |
| WO-2001027089-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-04-19 | — | — | WO | claimed |
| EP-1005470-A1 | OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ZENECA LIMITED (GB) | 2000-06-07 | — | — | EP | claimed |
| WO-1999010349-A1 | OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ZENECA LIMITED (GB) | 1999-03-04 | — | — | WO | claimed |
| EP-0861249-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-02 | — | — | EP | claimed |
| US-5753660-A | Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1998-05-19 | — | — | US | claimed |
| WO-1997018205-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-05-22 | — | — | WO | claimed |